Results 11 to 20 of about 36,481 (278)
CD73 Promotes Chronic Lymphocytic Leukemia
Cancers, 2022 The ecto-nucleotidase CD73 is an important immune checkpoint in tumor immunity that cooperates with CD39 to hydrolyze pro-inflammatory extracellular ATP into immunosuppressive adenosine. While the role of CD73 in immune evasion of solid cancers is well established, its role in leukemia remains unclear.
David Allard +7 more
openaire +3 more sources
CD73-Deficient Mice Are Resistant to Carcinogenesis [PDF]
Cancer Research, 2012 Abstract CD73 is a cell surface 5′-nucleotidase that converts AMP to adenosine, an immune suppressive molecule. CD73 may promote immune escape in cancer by contributing to the degradation of extracellular ATP released by dying cancer cells in hypoxic tumors or following chemotherapy.
Stagg, John +6 more
openaire +6 more sources
An Exceptionally Potent Inhibitor of Human CD73 [PDF]
Biochemistry, 2019 We recently reported the initiation of a Phase I clinical trial with AB680, a potent human CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973). We undertook a detailed kinetic analysis of the interaction between human CD73 and AB680 to determine the mode of inhibition.
Christine E. Bowman +3 more
openaire +5 more sources
The CD73 immune checkpoint promotes tumor cell metabolic fitness
eLife, 2023 CD73 is an ectonucleotidase overexpressed on tumor cells that suppresses anti-tumor immunity. Accordingly, several CD73 inhibitors are currently being evaluated in the clinic, including in large randomized clinical trials.
David Allard +6 more
doaj +2 more sources
CD73, a significant protein in liver diseases [PDF]
Frontiers in Medicine, 2023 Purine adenosine pathway exists widely in the body metabolism, and is involved in regulating various physiological processes. It is one of the important pathways of environmental regulation in human body. CD73 is essentially a protease that catalyzes further dephosphorylation of extracellular adenine nucleotides, hydrolyzing extracellular AMP to ...
Huilian Shi +4 more
openaire +4 more sources
Scientific ReportsCD73 is a cell-surface ectoenzyme that hydrolyzes the conversion of extracellular adenosine monophosphate to adenosine, which in turn can promote resistance to immune checkpoint blockade therapy.
Kyung-Ho Jung +6 more
doaj +2 more sources
Receptors & Clinical Investigation, 2015 Abstract Adenosine is a potent anti-inflammatory molecule that plays an important role in many diseases. Extracellular levels of adenosine are determined by a combination of membrane transporters and ecto-nucleotidases such as CD73. Therapeutic targeting of the adenosinergic pathway, such as administration of adenosine receptor agonists, could be a ...
Pavel Chrobak, John Stagg
openaire +3 more sources
CD73 Dysregulates Monocyte Anti-Tumor Activity in Multiple Myeloma
Cancer Management and Research, 2023 Lin Zhou,1,* XiaoLan Liu,2,* Tao Guan,2 HaiLing Xu,1 Fang Wei1 1Department of Hematology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Shanxi Key Laboratory of Precise and Diagnosis and Therapy of
Zhou L, Liu X, Guan T, Xu H, Wei F
doaj +1 more source
CD39 and CD73 in immunity and inflammation [PDF]
Trends in Molecular Medicine, 2013 The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced ...
Luca, Antonioli +3 more
openaire +2 more sources
Медицинская иммунология, 2022 Purinergic signaling modulates systemic and local inflammatory responses in immune-mediated and autoimmune diseases, including psoriasis. Extracellular ATP is an important factor of purinergic regulation, and its levels are regulated by catalytic effects
D. G. Kuptsova +5 more
doaj +1 more source